GRAIL (NASDAQ:GRAL) Stock Price Expected to Rise, Mizuho Analyst Says

GRAIL (NASDAQ:GRAL) had its price objective hoisted by Mizuho from $65.00 to $100.00 in a research note issued on Friday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Mizuho’s target price would suggest a potential downside of 20.13% from the stock’s previous close.

Several other brokerages also recently issued reports on GRAL. Robert W. Baird increased their price objective on shares of GRAIL from $96.00 to $118.00 and gave the stock an “outperform” rating in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a report on Friday, July 17th. Wolfe Research assumed coverage on GRAIL in a report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. TD Cowen reiterated a “buy” rating on shares of GRAIL in a report on Thursday. Finally, Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a research note on Sunday, September 13th. Five research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $78.60.

GRAIL Trading Up 15.4%

NASDAQ:GRAL opened at $125.21 on Friday. GRAIL has a 1 year low of $41.50 and a 1 year high of $126.81. The stock has a 50-day moving average price of $77.33 and a two-hundred day moving average price of $65.25. The stock has a market cap of $5.59 billion, a price-to-earnings ratio of -12.84 and a beta of 3.25.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%.The company had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. Sell-side analysts forecast that GRAIL will post -10.41 earnings per share for the current year.

Insider Buying and Selling at GRAIL

In other GRAIL news, CFO Aaron Freidin sold 4,100 shares of the company’s stock in a transaction on Monday, September 21st. The stock was sold at an average price of $93.34, for a total value of $382,694.00. Following the transaction, the chief financial officer directly owned 248,983 shares of the company’s stock, valued at $23,240,073.22. This represents a 1.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Joshua J. Ofman sold 61,452 shares of the firm’s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $97.74, for a total transaction of $6,006,318.48. Following the transaction, the chief executive officer directly owned 362,271 shares in the company, valued at approximately $35,408,367.54. This represents a 14.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 78,452 shares of company stock valued at $7,485,691 in the last ninety days. Insiders own 1.83% of the company’s stock.

Hedge Funds Weigh In On GRAIL

Hedge funds and other institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd bought a new stake in GRAIL during the fourth quarter worth $28,000. Fifth Third Bancorp increased its stake in shares of GRAIL by 15,733.3% in the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after purchasing an additional 472 shares during the last quarter. Allworth Financial LP bought a new position in shares of GRAIL in the 2nd quarter valued at $35,000. Geneos Wealth Management Inc. raised its holdings in shares of GRAIL by 160.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock worth $30,000 after buying an additional 360 shares in the last quarter. Finally, Osbon Capital Management LLC acquired a new position in shares of GRAIL during the 4th quarter worth $51,000.

Key Headlines Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: FDA advisers backed Galleri’s safety and narrowly endorsed the test’s efficacy, improving its prospects for full FDA approval. The close efficacy vote shows that effectiveness remains a key risk, but the recommendation represents an important regulatory milestone. FDA advisers back safety of GRAIL’s cancer test
• Positive Sentiment: Galleri’s final FDA decision is expected in the coming months. Approval could expand market access, encourage insurer adoption and materially increase GRAIL’s commercial opportunity. GRAIL’s multi-cancer blood test gets FDA committee vote
• Positive Sentiment: The FDA news helped drive a reported 55% weekly rally and pushed GRAIL to a new 52-week high, reflecting increased investor expectations for Galleri. Why GRAIL stock surged this week
• Positive Sentiment: Robert W. Baird raised its price target from $96 to $118 and maintained an outperform rating, citing a more favorable regulatory outlook.
• Neutral Sentiment: GRAIL also reported PATHFINDER 2 study findings, providing additional clinical data for investors evaluating Galleri’s effectiveness ahead of the FDA’s final decision. GRAIL reports PATHFINDER 2 study findings
• Neutral Sentiment: Reported short interest was zero shares as of September 24, suggesting little measurable short-selling pressure, although the figure may reflect a data-reporting issue.
• Negative Sentiment: CEO Joshua Ofman sold 61,452 shares worth about $6.0 million, while CFO Aaron Freidin sold 4,100 shares worth approximately $383,000. Both transactions occurred under pre-arranged Rule 10b5-1 plans, reducing their significance but potentially weighing on sentiment. GRAIL insider Joshua Ofman sells shares
• Negative Sentiment: Goldman Sachs initiated coverage with a hold rating, while the broader analyst consensus remains hold with an average target of $75.10—well below recent trading levels—indicating valuation and execution concerns after the rally.

About GRAIL

GRAIL, Inc is a healthcare company focused on developing blood-based tests for the early detection of cancer. Its technology uses genomic and epigenomic signals, including patterns of DNA methylation, to identify signals associated with multiple cancer types from a single blood sample.

The company’s primary product is Galleri, a prescription blood test designed to screen for signals of more than 50 types of cancer, including cancers that currently lack recommended screening methods. Galleri is intended to complement, not replace, guideline-recommended cancer screenings, and a positive result requires follow-up diagnostic testing to determine whether cancer is present and where it may be located.

GRAIL was founded in 2016 as a subsidiary of Illumina and became an independent publicly traded company following its separation from Illumina in 2021.